| Project/Area Number |
07557053
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
Circulatory organs internal medicine
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
SUGISHITA Yasuro University of Tsukuba Institute of Clinical Medicine Professor, 臨床医学系, 教授 (90010131)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
GOTO Katsutoshi University of Tsukuba Institute of Basic Medical Sciences Associate Professor, 基礎医学系, 教授 (30012660)
SAKAI Satoshi University of Tsukuba Institute of Clinical Medicine Research, 臨床医学系, 助手 (30282362)
MIYAUCHI Takashi University of Tsukuba Institute of Clinical Medicine Assistant Professor, 臨床医学系, 講師 (60222329)
粕谷 善俊 筑波大学, 基礎医学系, 講師 (70221877)
|
|---|
| Project Period (FY) |
1995 – 1997
|
| Project Status |
Completed (Fiscal Year 1997)
|
| Budget Amount *help |
¥9,400,000 (Direct Cost: ¥9,400,000)
Fiscal Year 1997: ¥2,600,000 (Direct Cost: ¥2,600,000)
Fiscal Year 1996: ¥6,800,000 (Direct Cost: ¥6,800,000)
|
|---|
| Keywords | cardiovascular diseases / endothelin / endothelin antagonist / heart failure / pulmonary hypertension / pharmacology / エンドセリレ拮抗薬 / 新治療法 / エンドセリン受容体遮断薬 |
|---|
| Research Abstract |
Endothelin (ET) is an endothelium-derived potent vasoconstrictor peptide. ET is also produced by non-vascular tissues such as the heart, lungs and kidneys. ET has mitogenic activity on vascular smooth muscle cells and induces hypertrophy of cardiac myocytes. In the present work, we studied pathophysiological roles of ET in the animals with various cardiovascular diseases (pulmonary hypertension, heart failure, cardiac hypertrophy, e.t.c.) using molecular biological and biochemical methods. Furthermore, we studied the effects of ET receptor antagonists on the animals with cardiovascular diseases. The present study suggested that endogenous ET is involved in the progression of cardiovascular diseases such as pulmonary hypertension, heart failure and cardiac hypertrophy, and that an ET receptor antagonist may be a useful drug for these theses.
|
